Medical Device Patents Surging, Industry Players Forecast The Future

With recent changes to US patent laws, a landmark US Supreme Court decision, and the emergence of so-called “patent trolls” in the medical device community, it seems everyone is talking patents. Medical device patents and litigation are “booming,” according to industry experts, and medtech companies need to pay close attention.

The need to protect intellectual property (IP) via patents has become an increasingly vital concern for the design process, business strategy, worth, and growth of all medical device companies, from garage-based start-ups to large publicly held companies. And, as the need for innovative, cost-effective technologies in health care has surged, so has the current and projected patent activity in this space, influenced in part by the recent significant changes in the US patent system under the America Invents Act (AIA). In fact, the number of device patents issued grew at a 15.7% rate between 2010 and 2012, with 60,300 patents assigned during this time period, according to the newly released fourth annual "State of Innovation" report by business information and news provider Thomson Reuters. What's more, the device category exhibited the strongest growth rate of the 12 key technology areas examined using the Thomson Reuters Derwent World Patents Index (DWPISM) database.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legal & IP

US Medtech Tariffs: How Will EU Navigate Unchartered Territory?

 

US President Trump has imposed sweeping tariffs that encompass medtech. These are expected to drive up costs, disrupt supply chains and hinder innovation, likely driving the EU to seek new trade partnerships to mitigate the impact.

Democrats Condemn Trump’s HHS Layoffs During House Hearing On OTC Drug User Fees

 

Energy and Commerce Health Subcommittee Democrats focus on criticizing HHS Secretary Kennedy’s RIF announcement, including 3,500 FDA jobs among cuts across HHS agencies. Representatives were left wondering if user fee programs would continue, even if reauthorized.

LDT Saga Comes To A Grinding Halt As Judge Sides With Labs, Vacates FDA’s Final Rule

 

A federal judge in Texas delivered what is most likely a fatal blow to the US FDA’s final rule, which would have regulated lab-developed tests as medical devices.

US Federal Trade Commission Challenges Surmodics-Biocoat Merger Over Antitrust Concerns

 
• By 

A planned merger between medical device coating manufacturers Surmodics and Biocoat is facing an antitrust lawsuit from the US Federal Trade Commission. The FTC believes the move would create an illegal monopoly.

More from Policy & Regulation

Medtech Strategy Must Be Priority, German Diagnostics Firms Tell Government

 
• By 

Germany’s incoming coalition government has reacted positively to industry’s calls for a dedicated medtech strategy to boost economic growth. Faster digitization, lower energy costs and “IVDR 2.0” are also on the in vitro diagnostic industry’s agenda.

FDA Reverses Course, Allows Some Telework For Reviewers

 

The new telework policy returns to the pre-COVID-19 pandemic standard, but still requires reviewers to be at White Oak for sponsor meetings and divisions to have an in-office presence every day.

Opportunity For Medtech To Contribute To EU Cybersecurity Recommendations

 

The deadline for comments is 30 June 2025